Tweets
-HS ttx👇
1. Lifestyle changes: smoking cessation, obesity.
2. Management of comorbidities.
3. 🔍HS- related autoimmune disorders.
4. FDA approved biologics:
-Adalimumab (PIONEER 1&2)
-Secukinumab (SUNRISE, SUNSHINE)
-Bimekizumab (BE HEARD 1&2)
"Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1
Links:
Adela Castro @AdelaCastro222 ( View Tweet )
11 months 2 weeks ago
1/3 of #axial #PsA
👇
No #SI joint changes , only #axial
@RheumNow #RNL2025
Catherine Blackwell
#ClinicalPearl https://t.co/YmoipL1bME
Janet Pope @Janetbirdope ( View Tweet )
11 months 2 weeks ago
Pregnancy is 🔥 inflammatory
Hard to interpret MRI of SI joints in setting of pregnancy
Ideally, don't score MRI during pregnancy or 1 year afterwards, would be affected by the pregnancy
If needed for clinical eval, focus on structural lesions like erosions
#RNL2025 @RheumNow
Eric Dein @ericdeinmd ( View Tweet )
11 months 2 weeks ago
Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidisciplinary, patient-centered treatment should includes a combination of pharmacological and nonpharmacological options. https://t.co/x4OVeQ5RJz https://t.co/i1fD6XQbnx
Dr. John Cush @RheumNow ( View Tweet )
11 months 2 weeks ago
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Links:
Eric Dein @ericdeinmd ( View Tweet )
11 months 2 weeks ago
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway @RichardPAConway ( View Tweet )
11 months 2 weeks ago
MDA5 + Pts with #ILD in #dermatomyositis can improve!
@RheumNow @ACRheum #RNL2025
Data from Christina Charles-Schoeman
#ClinicalPearl
Her pearls
👇
#DM is a #vascular #disease
#CK is not reliable in chronic DM
Neg Abs don’t r/o #myositis https://t.co/hxomz70aq5
Janet Pope @Janetbirdope ( View Tweet )
11 months 2 weeks ago
#RNL2025 @RheumNow
Dermatomyositis is VASCULAR disease
-IVIG may help DM by blocking complement deposition on endomysial capillaries
-CK levels not reliable
Pruritus common in up to 86% of DM patients
Dr. Charles-Schoeman, UCLA
Eric Dein @ericdeinmd ( View Tweet )
11 months 2 weeks ago
#RNL2025 @RheumNow
JAKi in DM:
@JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response
145 case reports for tofa, bari, ruxolitinib.
Role in helping calcinosis? Pruritu?
Brepocitinib (JAK1/TYK2i) study
Eric Dein @ericdeinmd ( View Tweet )
11 months 2 weeks ago
Pearls on Dermatomyositis:
-Negative myomarker does not r/o DM
-Pruritus can be a skin manifestation in DM🚨
-Combination therapy upfront =achieve faster remission
-Evidence for JAK inhibitors in management
-JAKis seem to have good effect in DM-calcinosis
-In DM with rapidly… https://t.co/J3iiDa6ph7 https://t.co/0WTHKa97bt
Links:
Adela Castro @AdelaCastro222 ( View Tweet )
11 months 2 weeks ago
Importance of not over-relying on lab tests. We can test for what we can test for, but this is not comprehensive. For me in clinical practice - Postive antibodies can confirm diagnosis of DM but negative cannot exclude it. @RheumNow #RNL2025 https://t.co/Kyfzne4BSD
Richard Conway @RichardPAConway ( View Tweet )
11 months 2 weeks ago
Do you want to know a secret? @drcharitydean shares that doctors are wired in the same way that #AI is built. We understand the layers of complexity & are best equipped to partner with AI. @rheumnow #RNL2025
TheDaoIndex @KDAO2011 ( View Tweet )
11 months 2 weeks ago
